Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
efineptakin alfa + nivolumab
- Development stage
- Unknown
- Lead developer
- NeoImmuneTech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
**efineptakin alfa + nivolumab** is an investigational combination therapy consisting of NT-I7 (efineptakin alfa), a novel long-acting human interleukin-7 (IL-7) cytokine, and nivolumab (Opdivo), a PD-1 blocking monoclonal antibody. NT-I7 is designed to promote T cell expansion and enhance immune responses, while nivolumab blocks PD-1 to restore anti-tumor T cell activity. The combination aims to synergistically enhance anti-tumor immunity. It is primarily being investigated for the treatment of advanced or metastatic gastric cancer, gastro-esophageal junction (GEJ) cancer, and esophageal adenocarcinoma. NeoImmuneTech is the primary developer of efineptakin alfa, and Bristol Myers Squibb developed nivolumab. Phase 2 clinical trials are ongoing to evaluate efficacy, safety, and tolerability in these cancer populations[2][5][9][8].
- Other names
- NT-I7 + nivolumabefineptakin alfa + Opdivo
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)IL7R (Interleukin-7 Receptor)
Beyond the preview
Go deeper on efineptakin alfa + nivolumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on efineptakin alfa + nivolumab.